Key result
Transcatheter aortic valve replacement (TAVR) significantly reduced overall mortality at 1 year compared to standard therapy among inoperable patients with symptomatic, severe aortic stenosis.
Why the study?
Does TAVR reduce overall mortality at 1 year in patients with symptomatic, severe aortic stenosis who are inoperable or high-risk candidates for AVR compared to standard therapy?
Does TAVR reduce overall mortality at 1 year in patients with symptomatic, severe aortic stenosis who are inoperable or high-risk candidates for AVR compared to standard therapy?
TAVR significantly reduces overall mortality at 1 year compared to standard therapy in inoperable patients with severe symptomatic aortic stenosis.
May support TAVR consideration in inoperable severe AS; leaves open durability, cost, and selection questions for prospective study.
Calcific aortic stenosis (AS) is the most common form of valvular heart disease requiring intervention in the developed world. Although indolent early in its course, the disease becomes extremely malignant following the development of symptoms with an average survival of only 2–3 years and a high rate of sudden death. Until recently, surgical aortic valve replacement (AVR) had been the only therapy demonstrated to alter the natural history of AS and improve mortality. Standard medical therapy, including balloon aortic valvuloplasty, can lead to a short-term improvement in symptoms, but does not improve survival. The Placement of Aortic Transcatheter Valves (PARTNER) trial compared transcatheter aortic valve replacement (TAVR) with standard therapy in patients with symptomatic, severe AS who were inoperable (cohort B) or high-risk (cohort A) candidates for AVR. In cohort B of the trial, TAVR with the Edwards SAPIEN valve significantly reduced the primary end point of overall mortality at 1 year among patie...
No takes yet. Share an insight, caveat, or question.
Nazif et al. (2011) conducted a review in Symptomatic, severe aortic stenosis. Transcatheter aortic valve replacement (TAVR) vs. Standard therapy was evaluated on Overall mortality. Transcatheter aortic valve replacement (TAVR) significantly reduced overall mortality at 1 year compared to standard therapy among inoperable patients with symptomatic, severe aortic stenosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: